Telisotuzumab-Optional treatment options and clinical research summary after EMRELIS resistance

Telisotuzumab Vedotin, trade name EMRELIS) is an antibody drug conjugate (ADC), consisting of a monoclonal antibody targeting the c-Met receptor and a microtubule inhibitor MMAE (monomethyl auristatin E) coupling. c-MetThe receptor is highly expressed in a variety of tumor cells, especially in non-small cell lung cancer (NSCLC). Some patients show c-Met overexpression or MET gene amplification, leading to tumor growth, metastasis and drug resistance. EMRELISBy specifically binding to c-Met receptors, cytotoxic drugs can be accurately delivered to tumor cells and induce apoptosis, thereby achieving anti-tumor effects.

Clinical studies have shown that EMRELISshows a high objective response rate (ORR) and a controllable safety profile in patients with c-Metoverexpressed advanced or metastatic NSCLC. During initial treatment, patients achieved disease response or a significant reduction in tumor burden with EMRELIS. However, as the treatment time is prolonged, some patients may develop drug resistance. The main mechanisms include downregulation of c-Met expression, obstruction of ADC internalization, or cell resistance to microtubule inhibitors. This resistance limits the sustained efficacy of single-agent therapy and requires consideration of next treatment strategies.

For EMRELIS resistant patients, a variety of clinical options can be adopted. First, replacing or combining other targeted drugs is a feasible strategy. For example, for patients with c-Met amplification or mutation, other c-Met inhibitors such as capmatinib or Crizotinib (Crizotinib), these small molecule inhibitors can inhibit the c-Met signaling pathway through different mechanisms and compensate for EMRELISThe efficacy gap after drug resistance. At the same time, for some patients with EGFR mutations or ALK rearrangements, corresponding targeted drugs can be selected based on molecular characteristics to achieve personalized treatment.

Secondly, combination chemotherapy or immunotherapy is also a common solution. Patients with drug-resistant EMRELIS can still receive platinum-based combination chemotherapy or paclitaxel-based regimens under the guidance of doctors to prolong disease control time. In addition, some studies have explored the combined use of EMRELIS and PD-1/PD-L1 immune checkpoint inhibitors to try to enhance the anti-tumor immune response and improve the prognosis of drug-resistant patients. Clinical trial data show that combination therapy can provide a certain response rate in drug-resistant patients, but adverse reactions such as bone marrow suppression, peripheral neurotoxicity, and immune-related adverse events need to be closely monitored.

In addition, for some suitable patients, clinical trial participation is also an important way. A number of clinical studies targeting EMRELIS-resistant or c-Met-related tumors are ongoing around the world, including exploring combinations of new ADCs, bispecific antibodies and small molecule inhibitors. This provides new treatment options for drug-resistant patients and helps accumulate richer efficacy and safety data.

In summary, the treatment strategy for patients with resistance to terituzumab (EMRELIS) should be individually selected based on molecular characteristics, resistance mechanisms and patient physical conditions. Possible options include replacing or combining with other c-Met inhibitors, combining chemotherapy or immunotherapy, and participating in clinical trials. Clinical studies have shown that these strategies have the potential to prolong patient survival and improve quality of life, but adverse reactions still need to be strictly monitored in professional medical institutions to ensure both efficacy and safety. In the future, with the continuous development of new ADCs and combination therapies, the treatment prospects for EMRELIS-resistant patients will be even brighter.

Reference materials:https://www.drugs.com/